ASCO GU 2021 Bladder Cancer - Results from #20

Viewing 21-40 of 50 articles

ASCO GU 2021: Heterogeneity in Nectin-4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin

ASCO GU 2021: Phase II/III Clinical Results of IL-15RαFc Superagonist N-803 With BCG in BCG-Unresponsive NMIBC Carcinoma In Situ Patients

ASCO GU 2021: Characterization of FOXF1 as a Novel Regulator of Nodal Metastasis in Bladder Cancer

ASCO GU 2021: Avelumab First-Line Maintenance Plus Best Supportive Care vs Best Supportive Care Alone For Advanced Urothelial Carcinoma: JAVELIN Bladder 100 Subgroup Analysis Based On Duration And Cycles Of First-Line Chemotherapy

ASCO GU 2021: Association Between Tumor Mutational Burden and Immune-Related Adverse Events in Patients with Metastatic Urothelial Carcinoma During Checkpoint Immunotherapy

ASCO GU 2021: Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder

ASCO GU 2021: Invited Discussion: Enfortumab Vedotin in Previously Treated Urothelial Cancer

ASCO GU 2021: Pembrolizumab for the Treatment of Patients with High-Risk Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guérin: Extended Follow-up of KEYNOTE-057 Cohort A

ASCO GU 2021: SURE: An Open Label, Sequential-Arm, Phase II Study of Neoadjuvant Sacituzumab Govitecan, and Sacituzumab Govitecan plus Pembro Before Radical Cystectomy, for Patients with MIBC Who Cannot Receive or Refuse Cisplatin-Based Chemotherapy

ASCO GU 2021: Updated Outcomes of POUT: A Phase III Randomized Trial of Peri-Operative Chemotherapy Versus Surveillance in Upper Tract Urothelial Cancer

ASCO GU 2021: Alignment and Discordances in Perceptions and Experiences of Shared Decision Making Among Bladder Cancer Patients and Their Care Team

ASCO GU 2021: EV-201 Cohort 2: Enfortumab Vedotin In Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer Who Received Prior PD-1/PD-L1 Inhibitors

ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Systemic

ASCO GU 2021: Safety and Efficacy Of Perioperative Cisplatin/Gemcitabine And Durvalumab For Operable Muscle-Invasive Urothelial Carcinoma: SAKK 06/17

ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

ASCO GU 2021: Atezolizumab Monotherapy vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Outcomes by PD-L1 Status In Cisplatin-Ineligible Patients From the Phase III IMvigor130 Study

ASCO GU 2021: Optimal Therapy for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer in the Non-cystectomy Candidate - Intravesical

ASCO GU 2021: Approaches to Immune Checkpoint Inhibitor Maintenance Therapy in Metastatic Urothelial Cancer: A Qualitative Analysis of Oncology Providers in the United States

ASCO GU 2021: Best of Journals: Urothelial Cancer - Surgery

ASCO GU 2021: Best of Journals: Urothelial Cancer - Radiation Oncology

1
2
3